EWTX Edgewise Therapeutics Inc

$EWTX The remaining $1.1 billion of payments by Servier to Edgewise for the muscular dystrophy business are divided into the following milestones: * FDA approval of Sevasemten for Becker muscular dystrophy (expected in early 2029): Up to $200 million * FDA approval of Sevasemten for Duchenne muscular dystrophy (expected in late 2030): Up to $600 million * Commercial sales target: $300 million after annual U.S. net sales exceed $550 million

$EWTX Following Servier’s acquisition of EWTX’s muscular distrophy business, Chris Martin remained as a member of EWTX’s Board of Directors rather than moving to Servier. The reason for that is because he has been serving in a corporate governance role rather than in an operations role. I followed Chris’s work at Verona Pharma, and I believe he played a pivotal role in Verona’s ascension from a $5 - $10 stock to a $100+ stock.

$EWTX taking a hit with a 2.32% drop today Over 5% down for the week No news driving it, just pure downside momentum Traders, watch the volatility if you're thinking of going long Options flow is quiet Only one small far-OTM call out there A 270-contract Sep 18 $55 call Barely a blip, so don't count on it for any bullish signals Stick to price action if you're trading this one